TY - JOUR T1 - Epidemiological characteristics of 1212 COVID-19 patients in Henan, China JF - medRxiv DO - 10.1101/2020.02.21.20026112 SP - 2020.02.21.20026112 AU - Pei Wang AU - Jun-an Lu AU - Yanyu Jin AU - Mengfan Zhu AU - Lingling Wang AU - Shunjie Chen Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/02/23/2020.02.21.20026112.abstract N2 - Based on publicly released data for 1212 patients, we investigated the epidemiological characteristics of COVID-19 in Henan of China. The following findings are obtained: 1) COVID-19 patients in Henan show gender (55% vs 45%) and age (81% aged between 21 and 60) preferences, possible causes were explored; 2) Statistical analysis on 483 patients reveals that the estimated average, mode and median incubation periods are 7.4, 4 and 7 days; Incubation periods of 92% patients were no more than 14 days; 3) The epidemic of COVID-19 in Henan has undergone three stages and showed high correlations with the numbers of patients that recently return from Wuhan; 4) Network analysis on the aggregate outbreak phenomena of COVID-19 revealed that 208 cases were clustering infected, and various people’s Hospital are the main force in treating patients. The related investigations have potential implications for the prevention and control of COVID-19.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThis is an epidemiological study on patients with COVID-19 in Henan, ChinaFunding StatementThis work was supported by the National Natural Science Foundation of China (Grant Nos. 61773153, 61773175, 61573262). The Supporting Plan for Scientific and Technological Innovative Talents in Universities of Henan Province (Grant No. 20HASTIT025), and the Training Plan of Young Key Teachers in Colleges and Universities of Henan Province (Grant No. 2018GGJS021). Partly supported by the supporting grant of Bioinformatics Center of Henan University (Grant No. 2018YLJC03).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are publicly available from the all levels of CDCs' websites in Henan of China ER -